Trial reportEuropean journal of endocrinology2022
Effect of obstructive sleep apnea on glucose metabolism.
Trial report in European journal of endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Mechanisms Linking Sleep-Disordered Breathing and Cardiometabolic Disease Risk.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- Association between metabolic dysfunction-associated steatotic liver disease and obstructive sleep apnea: a nationwide retrospective cohort study.Scientific reports · 2026Article
- The role of red blood cell distribution width in prognosis prediction among critically ill patients with obstructive sleep apnea: Insights from the MIMIC-IV database.Scientific reports · 2026Article
- Muscle quality decline and fat infiltration in non-elderly OSA patients: associations with metabolic abnormalities.Journal of translational medicine · 2025Article
- A Structured Narrative Review of the OSA-T2DM Axis.Journal of clinical medicine · 2025Review
- Impact of Obstructive Sleep Apnea and Triglyceride Glucose Index on Cardiovascular Events in Acute Coronary Syndrome Patients: A Post-Hoc Analysis of the OSA-ACS Study.Reviews in cardiovascular medicine · 2025Article
- Letter to the Editor Regarding: "Association Between Metabolic Score for Insulin Resistance (METS-IR) and Risk of Obstructive Sleep Apnea: Analysis of NHANES Database and a Chinese Cohort" [Response to Letter].Nature and science of sleep · 2025Article
- NLRP3 Inflammasome Triggers Inflammation of Obstructive Sleep Apnea.Current molecular medicine · 2025Review
- Exploring the Association Between Triglyceride-Glucose Indices and Their Derivatives With Obstructive Sleep Apnea: Insights From the National Health and Nutrition Examination Survey.Nature and science of sleep · 2025Article
- Sleep Disorders in Connective Tissue Diseases-Coexisting Diseases or Disease Components?Journal of clinical medicine · 2024Review
- The benefits of hypoglycemic therapy for patients with obstructive sleep apnea.Sleep & breathing = Schlaf & Atmung · 2024Review
- Approach the Patient With Obstructive Sleep Apnea and Obesity.The Journal of clinical endocrinology and metabolism · 2024Article
- Association of Obstructive Sleep Apnea with Nonalcoholic Fatty Liver Disease: Evidence, Mechanism, and Treatment.Nature and science of sleep · 2024Review
- The determinants of fasting and post-load non-esterified fatty acids in older adults: The cardiovascular health study.Metabolism open · 2023Article
- Investigating the Relationship between Obstructive Sleep Apnoea, Inflammation and Cardio-Metabolic Diseases.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundObstructive sleep apnea (OSA) is prevalent in people with obesity and is a major risk factor for type 2 diabetes (T2D). The effect of OSA on metabolic function and the precise mechanisms (insulin resistance, β-cell dysfunction, or both) responsible for the increased T2D risk in people with OSA are unknown. DESIGN AND
methodsWe used a two-stage hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotopically labeled glucose and palmitate tracer infusions and 18F-fluorodeoxyglucose injection and positron emission tomography to quantify multi-organ insulin action and oral and intravenous tolerance tests to evaluate glucose-stimulated insulin secretion in fifteen people with obesity and OSA and thirteen people with obesity without OSA.
resultsOSA was associated with marked insulin resistance of adipose tissue triglyceride lipolysis and glucose uptake into both skeletal muscles and adipose tissue, whereas there was no significant difference between the OSA and control groups in insulin action on endogenous glucose production, basal insulin secretion, and glucose-stimulated insulin secretion during both intravenous and oral glucose tolerance tests.
conclusionsThese data demonstrate that OSA is a key determinant of insulin sensitivity in people with obesity and underscore the importance of taking OSA status into account when evaluating metabolic function in people with obesity. These findings may also have important clinical implications because disease progression and the risk of diabetes-related complications vary by T2D subtype (i.e. severe insulin resistance vs insulin deficiency). People with OSA may benefit most from the targeted treatment of peripheral insulin resistance and early screening for complications associated with peripheral insulin resistance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.